专题：专题|2024年度A股CFO数据报告：美的集团钟铮年薪946万，比亚迪周亚琳896万 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 作为上市公司核心管理层关键成员，财务总监CFO的地位与作用至关重要。新浪财经《2024年度A股 CFO数据报告》显示，2024年A股上市公司财务总监CFO群体薪酬规模合计达42.70亿元，平均年薪为 81.48万元。 沈阳兴齐眼药股份有限公司（证券代码：300573.SZ）近日披露的财务数据显示，公司财务总监程亚男 2024年薪酬达188.02万元，较2023年增长18.12万元，增幅达10.67%。这一数据与公司股价表现形成鲜 明对比——2024年公司股价累计下跌61.73%，市值缩水至122.29亿元。 公开资料显示，现年51岁的程亚男自2011年11月起担任公司财务总监，目前同时兼任董事、副总经理职 务。作为公司核心管理层成员，其薪酬水平已显著高于A股市场平均水平。 值得关注的是，兴齐眼药2024年经营业绩呈现增长态势。年报显示，公司实现营业收入19.43亿元，同 比增长32.42%；归母净利润3.38亿元，同比增长40.84%。这种业绩增 ...

Core Viewpoint - The market shows a strong sentiment with significant sector rotation, indicating potential investment opportunities in undervalued sectors like photovoltaics and technology [1][2]. Group 1: Market Performance - As of July 29, 2025, the CSI A500 Index (000510) increased by 0.14%, with notable gains in stocks such as Tianfu Communication (300394) up 12.77% and Tiger Medical (300347) up 11.05% [1]. - The A500 ETF fund (512050) rose by 0.10%, with the latest price at 1.02 yuan [1]. Group 2: Sector Analysis - Short-term analysis suggests a significant rotation effect in the market, with a focus on undervalued sectors like photovoltaics for potential valuation recovery [1]. - Long-term, the technology sector is expected to provide narrative effects, with recommendations for a barbell strategy that includes increasing allocations to technology and communication sectors while maintaining dividend stock allocations [1]. Group 3: Index Composition - As of June 30, 2025, the top ten weighted stocks in the CSI A500 Index include Kweichow Moutai (600519), Contemporary Amperex Technology (300750), and Ping An Insurance (601318), collectively accounting for 20.67% of the index [2]. - The top ten stocks by weight are as follows: - Kweichow Moutai: 0.09% increase, 3.81% weight - Contemporary Amperex Technology: 1.58% increase, 2.88% weight - Ping An Insurance: 0.73% decrease, 2.58% weight - China Merchants Bank: 0.20% decrease, 2.46% weight - Industrial Bank: 0.61% decrease, 1.68% weight - Yangtze Power: 0.07% increase, 1.59% weight - Midea Group: 0.76% decrease, 1.53% weight - Zijin Mining: 1.06% decrease, 1.39% weight - BYD: 0.79% increase, 1.30% weight - Eastmoney Information: 0.62% decrease, 1.26% weight [4].

A股眼科概念震荡反弹，天目药业涨停，兴齐眼药、莱美药业、诺思兰德、大恒科技等跟涨。 ...

Core Insights - The increasing prevalence of electronic devices has heightened awareness of the potential visual hazards associated with prolonged screen exposure, leading to a surge in demand for lutein as a vital nutrient for eye health [1][3] - The children's market for lutein products has become a competitive battleground, driven by rising concerns among parents regarding children's vision health [1][15] Market Overview - The domestic market for lutein is estimated to reach nearly 6 billion yuan, with a compound annual growth rate (CAGR) of 19.8% from 2020 to 2024, significantly outpacing global market growth [4][3] - The eye care sector is the primary contributor to market growth, with annual sales of lutein soft capsules exceeding 200 million bottles [4] Competitive Landscape - The lutein market is characterized by intense competition across both health food and regular food sectors, with no dominant brand currently leading the market [2][20] - Major players in the extraction and processing segment include Chenguang Biotech, DSM, and Kemin, creating a "three-legged" competitive structure [4] Product Development - The market has seen a rapid increase in the registration of lutein health products, with over 150 products registered, primarily in capsule form [7][8] - Innovative product forms such as gummies and ready-to-drink beverages are gaining popularity, with the market for lutein gummies expected to exceed 1.5 billion yuan by 2024 [11] Consumer Trends - The demand for lutein products is driven by the rising incidence of myopia among children, with the overall myopia rate in Chinese children reaching 51.9% [18] - The average price of imported lutein products is significantly higher than that of domestic products, with imported items often exceeding 100 yuan per unit [17] Regulatory Environment - Lutein products are primarily classified as health foods and must undergo a registration process, as they are not included in the approved health food ingredient directory [9][14] - The lack of a clear definition for dietary supplements in China has led to many imported lutein products being marketed as regular foods, despite their health claims [13] Future Outlook - The lutein market is expected to continue evolving, with a focus on product differentiation and innovation to address the challenges of market saturation and consumer trust [20][22] - Companies are encouraged to invest in research and development to create unique products that can withstand competition and avoid the pitfalls of market homogenization [22]

Group 1 - Hengbang Co., Ltd. plans to establish a joint venture with Huasheng Development with a registered capital of 10 million yuan, where Hengbang will contribute 8 million yuan (80%) and Huasheng will contribute 2 million yuan (20%) [1] - Hunan Gold's subsidiary Anhua Zhazi Creek Smelting Plant will undergo temporary maintenance starting from the end of June 2025, expected to last no more than 30 days [2] - Defu Technology's subsidiary signed supply agreements for lithium battery copper foil products with two leading global companies, with contract durations of 3 years and 5 years respectively [3] Group 2 - Binjiang Group won the rights to two residential land parcels for a total price of 4.368 billion yuan [5] - Zhong'an Technology announced the resignation of its executive vice president and board secretary due to personal reasons [7] - Changqing Technology's project for special polymer materials and electronic materials has officially commenced production, adding a capacity of 120,500 tons per year [10] Group 3 - Gansu Energy received approval from the China Securities Regulatory Commission to publicly issue bonds totaling up to 2 billion yuan [10] - Shuoshi Biology obtained a medical device registration certificate for an in vitro diagnostic reagent, valid until June 2030 [12] - Yawen Co., Ltd. plans to issue shares to specific investors, with the application accepted by the Shenzhen Stock Exchange [13] Group 4 - Guoyao Modern's subsidiary received approval for the listing of a raw material drug, which is a selective anticholinergic agent [16] - Inner Mongolia First Machinery's subsidiary signed a railway freight car procurement contract worth 130 million yuan [18] - Xining Special Steel plans to raise up to 1 billion yuan through a private placement to its controlling shareholder [39] Group 5 - Huadong Medicine's subsidiary received approval for a clinical trial of a new injectable drug targeting advanced solid tumors [29] - Warner Pharmaceutical's compound potassium hydrogen phosphate injection passed the consistency evaluation for generic drugs [30] - North Special Technology plans to raise up to 300 million yuan through a private placement for a production base project in Thailand [30] Group 6 - Xiangyang Technology is the first candidate for a 533 million yuan Airbus project [45] - Haishun New Materials intends to acquire 100% of Guangdong Zhengyi Packaging [46] - Jida Zhengyuan's shareholder plans to reduce their stake by up to 0.73% due to personal financial needs [47]

Core Viewpoint - The company has initiated the Phase II clinical trial for its SQ-22031 eye drops, aimed at treating neurotrophic keratitis (NK), with the first subject enrolled in the trial [1] Group 1: Product Development - SQ-22031 eye drops are designed to promote the growth and survival of sensory and sympathetic neurons, restoring damaged neuron function, which can lead to rapid healing of corneal damage and improvement in corneal sensation and tear production [1] - As of the announcement date, there are no approved competing products for SQ-22031 eye drops in the market according to the National Medical Products Administration [1] Group 2: Clinical Trial Progress - The company has completed the enrollment of the first subject in the randomized, double-blind, placebo-controlled Phase II clinical trial for SQ-22031 eye drops [1] - The initiation of the Phase II clinical trial is not expected to have a significant impact on the company's recent financial performance [1]

沈阳兴齐眼药股份有限公司（以下简称"公司"）研发的SQ-22031滴眼液于 今日完成了"评估SQ-22031滴眼液治疗神经营养性角膜炎（NK）患者的随机、双 盲、安慰剂、平行对照Ⅱ期临床试验"首例受试者入组，正式进入Ⅱ期临床试验。 现将有关内容公告如下： 证券代码：300573 证券简称：兴齐眼药 公告编号：2025-031 沈阳兴齐眼药股份有限公司 关于 SQ-22031 滴眼液治疗神经营养性角膜炎Ⅱ期临床试验首例 受试者入组的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、基本情况 药物名称：SQ-22031 滴眼液 注册分类：治疗用生物制品 1 类 剂型：眼用制剂 适应症：神经营养性角膜炎 临床试验批准通知书编号：2024LP01687、2024LP01688、2024LP01689、 2024LP01690 临床试验分期：Ⅱ期 二、临床试验相关情况 神经营养性角膜炎（Neurotrophic Keratitis，NK）是由三叉神经损伤引起 的角膜退行性疾病。本病特征是角膜知觉减退或缺失，出现干眼、角膜上皮缺损 和角膜溃疡，最终引起角膜基质融解 ...

证券代码：300573 证券简称：兴齐眼药 公告编号：2025-030 沈阳兴齐眼药股份有限公司 关于盐酸利多卡因眼用凝胶Ⅲ期临床试验首例受试者入组的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 沈阳兴齐眼药股份有限公司（以下简称"公司"）研发的盐酸利多卡因眼用 凝胶于今日完成了"评价盐酸利多卡因眼用凝胶用于眼表麻醉的有效性和安全性 的随机、双盲、阳性药平行对照、安慰剂平行对照、多中心临床试验"的首例受 试者入组，正式进入Ⅲ期临床试验。现将有关内容公告如下： 一、基本情况 药物名称：盐酸利多卡因眼用凝胶 注册分类：化学药品 3 类 二、临床试验相关情况 盐酸利多卡因是一种酰胺类局部麻醉药，被广泛用于浸润麻醉、硬膜外麻醉、 表面麻醉及神经传导阻滞。盐酸利多卡因眼用凝胶可延长药物与眼表面接触时间， 改善麻醉效果。 盐酸利多卡因眼用凝胶Ⅲ期临床试验为一项随机、双盲、阳性药平行对照、 安慰剂平行对照、多中心临床试验，以评价盐酸利多卡因眼用凝胶用于眼表麻醉 的有效性和安全性。 三、同类药品的情况 1 本次公告的盐酸利多卡因眼用凝胶是以盐酸利多卡因为活性成份的眼用 ...

Core Viewpoint - The A-share market has experienced significant structural changes over the past decade, with only a few industries surpassing their historical highs from 2015, while a select group of companies have demonstrated strong growth potential despite overall index stagnation [1][2]. Industry Performance - The top three performing industries from June 2015 to June 2025 are Food & Beverage, Home Appliances, and Banking, with most other industries failing to exceed their 2015 peak levels [1]. - Over the past ten years, more than 170 leading stocks in sectors such as Communication, Electronics, Biomedicine, and Machinery have achieved cumulative gains exceeding 300%, driven by macroeconomic transformation and industrial upgrades [2]. - The Food & Beverage sector has shown resilience due to its essential consumption characteristics, with leading companies in sub-sectors like liquor and snacks significantly outperforming major indices [4][6]. Notable Stocks - The top five stocks in the Food & Beverage sector over the past decade include: - Salted Fish (盐津铺子): 1,430.52% - Shanxi Fenjiu (山西汾酒): 863.43% - Kweichow Moutai (贵州茅台): 629.72% - Wanchen Group (万辰集团): 588.50% - Dongpeng Beverage (东鹏饮料): 572.38% [5][6]. - In the Home Appliances sector, Midea Group (美的集团) has led with a cumulative increase of 292.31% since 2015, while other notable companies have also seen significant gains [6]. Banking Sector Insights - The banking sector has outperformed many expectations, with the banking index reaching a historical high of 7,237.72 points, reflecting an 11.66% increase year-to-date and a 61.4% increase since last year [11]. - Notably, 39 out of 42 banking stocks have risen this year, with a significant portion of banks achieving over 200% growth since 2015 [11][12]. - The top-performing bank, China Merchants Bank, has seen a cumulative increase of 224.14%, while major state-owned banks have also doubled in value over the same period [12].

中国北京市朝阳区建国路 77 号华贸中心 3 号写字楼 34 层 邮政编码 100025 电话: (86-10) 5809-1000 传真: (86-10) 5809-1100 关于沈阳兴齐眼药股份有限公司 2025 年第一次临时股东大会的法律意见书 致：沈阳兴齐眼药股份有限公司 根据《中华人民共和国证券法》《中华人民共和国公司法》（以下简称 "《公司法》"）以及中国证券监督管理委员会颁布的《上市公司股东会规则》 （以下简称"《股东会规则》"）的规定，北京市竞天公诚律师事务所（以下 简称"本所"）指派律师出席了沈阳兴齐眼药股份有限公司（以下简称"公 司"）2025年第一次临时股东大会（以下简称"本次股东大会"），并就本次 股东大会的有关事宜出具本法律意见书。 本所在此同意，公司可以将本法律意见书作为本次股东大会公告的法定文 件，随其他公告文件一并提交深圳证券交易所予以审核公告。 本所律师根据《股东会规则》第六条的要求，按照律师行业公认的业务标 准、道德规范和勤勉尽责精神，对本次股东大会召集和召开的有关事实及公司 提供的文件进行了核查和验证，现出具法律意见如下： 一、本次股东大会的召集、召开程序 1、本次股东大 ...